Jamie Myers Describes the Design of Her CRCI Study
Jamie Myers Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study
Jamie Myers Explains Results From Her CRCI Study
Jamie Myers Explains Results From Her Chemotherapy-Related Cognitive Impairment Study
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo